Gaining depth on gain of function
Yesterday I posted “The fallacious Fauci strikes again.” My comments elicited a message from Michael S. Rogers, Assistant Professor of Surgery at Harvard Medical School and Research Associate in the Vascular Biology Program at Boston Children’s Hospital. I thought some readers might find it of interest. With his permission I am posting his message below the break.
The question of whether the 2017 PLoS Pathogens paper contains gain of function experiments has recently been in the news. Since I have significant experience (30 years) in the recombinant DNA techniques in question, I thought I might lay out what was done in the experiments and let you decide.
Mike Levin on electrifying insights into how bodies form harvard.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from harvard.edu Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: A research team at the Wyss Institute and Harvard Medical School has developed a nasal swab collection technology enabling high-throughput automated sample processing for molecular diagnosis of respiratory diseases including. view more
Credit: Wyss Institute at Harvard University
(Boston) The Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) and the Massachusetts-based startup Rhinostics announced today that the University s sample collection swab and high-throughput automation technologies have been licensed to Rhinostics. The company will further develop and commercialize automated and multiplexed solutions for processing nasal samples from people suspected to have COVID-19 or other respiratory infectious diseases. The license was coordinated by Harvard s Office of Technology Development (OTD) in accordance with the University s commitment to the COVID-19 Technology Access Framework.
Harvard University licenses its nasal swab collection technology, developed at the Wyss Institute and Harvard Medical School, to Mass startup Rhinostics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Emulate Names Donald Ingber to Board of Directors
Technology Visionary will Offer Strategic Insight to Guide Ongoing Research & Development of Market Leading Organ-on-a-Chip Technology
News provided by
Share this article
Share this article
BOSTON, Feb. 18, 2021 /PRNewswire/ Emulate, Inc., a leading provider of organ-on-a-chip technology today announced the appointment of Donald Ingber, M.D., Ph.D., to its Board of Directors. Ingber, the scientific founder of Emulate and Chairman of its Scientific Advisory Board is a pioneer in the field of biologically inspired engineering. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine.